Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Phase 2 Unknown 118 enrolled Shanghai Chest Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary endpoint is to compare the PFS (progress-free survival ) of etoposide plus carboplatin with paclitaxel combined with carboplatin as first-line treatment for advanced pulmonary large cell neuroendocrine carcinoma.

Timeline

Start: 2016-12
Primary completion: 2018-12
Completion: 2018-12

Publications

Results Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F. Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy. J Thorac Oncol. 2015 Aug;10(8):1133-41. doi: 10.1097/JTO.0000000000000589.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etoposide	Small molecule	100 mg/m2	Other
Subject	Paclitaxel	Small molecule	175 mg/m2	Other
Background	Carboplatin	Small molecule	5 unknown	Other

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Summary

Timeline

Publications

Drugs

Indications